EFFICACY OF CASPOFUNGIN AS SALVAGE THERAPY IN INVASIVE ASPERGILLOSIS COMPARED TO STANDARD THERAPY INHISTORICAL COHORT

J.Hiemenzt, I.Road, M.Boogaerts, J.Maertens, A.Saab, C.A.Sable, J.A.Chodakewiti, M.Severino, P.Saddler, R.Bermati, M.L.Nubile, T.F.Patterson, D.Denning, and T.J.Walsh

Abstract: 

Background: Caspofungin, an investigational echinocandin, has activity against Aspergillus species in vitro and in animal models. Caspofungin was evaluated in a noncomparative salvage study of patients with invasive aspergillosis (PO 19). An approximate comparator group of efficacy was identified from a historical cohort (HC) through a retrospective medical chart review. Methods: (n P019, 63 patients who were refractory (53) or intolerant (10) to other anti fungal therapies received caspoCungin 70 mg IV x 1 then 50 mg qd. The HC enrolled 214 patients who had received at least I week of standard antifungal therapy. In both studies, all patients had documented invasive aspergillosis (probable pulmonary or definite disease at any site). A favorable response (whether complete or partial) required clinical and radiological improvement. Diagnosis and outcome were confirmed by independent expert review in both P019 and HC. Logistic regression analysis, adjusting for prognostic factors identified in the HC, was used to compare expert assessments of efficacy between studies. Results: 'Me distribution of underlying conditions, the frequency of neutropenia (ANC
2001

abstract No: 

NULL

Full conference title: 

Focus on Fungal Infections 11, March 14-16 2001
    • Focus on Fungal Infection 11 (2001)